Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 18/20 | 0.69 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.51 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.51 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CPB1 | P15086 | 1/20 | 0.51 |
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
| ▸ | MMP3 | P08254 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3204849 | 0.86 | CPB2 (0.67) | CPB2CYP3A4CPB1 | |
| SCHEMBL3208045 | 0.85 | CPB2 (0.73) | CPB2CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL3208025 | 0.85 | CPB2 (0.73) | CPB2CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL3213903 | 0.82 | CPB2 (0.71) | CPB2CYP3A4CPB1 | |
| SCHEMBL3213887 | 0.82 | CPB2 (0.71) | CPB2CYP3A4CPB1 | |
| SCHEMBL3211162 | 0.82 | CPB2 (0.82) | CPB2CYP3A4CPB1 | |
| SCHEMBL3211133 | 0.82 | CPB2 (0.82) | CPB2CYP3A4CPB1 | |
| SCHEMBL3209744 | 0.82 | CPB2 (1.00) | CPB2CYP3A4CPB1 | |
| SCHEMBL3211782 | 0.81 | CPB2 (0.84) | CPB2CYP3A4CPB1 | |
| SCHEMBL27781388 | 0.81 | CPB2 (0.84) | CPB2CYP3A4CPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389764-B2 | Urea and sulfamide derivatives as inhibitors of TAFIa | SANOFI (FR) | 2013-03-05 | — | — | US | claimed |
| US-20100035930-A1 | UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa | SANOFI-AVENTIS (FR) | 2010-02-11 | — | — | US | claimed |
| CN-101553219-A | Urea and sulfamide derivatives as TAFIa inhibitors | SANOFI AVENTIS (FR) | 2009-10-07 | — | — | CN | claimed |
| US-8389764-B2 | Urea and sulfamide derivatives as inhibitors of TAFIa | SANOFI (FR) | 2013-03-05 | — | — | US | disclosed |
| US-8389764-B2 | Urea and sulfamide derivatives as inhibitors of TAFIa | SANOFI (FR) | 2013-03-05 | — | — | US | disclosed |
| US-20100035930-A1 | UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa | SANOFI-AVENTIS (FR) | 2010-02-11 | — | — | US | disclosed |
| US-20100035930-A1 | UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa | SANOFI-AVENTIS (FR) | 2010-02-11 | — | — | US | disclosed |
| WO-2008067909-A2 | UREA AND SULFAMIDE DERIVATIVES AS TAFIA INHIBITORS | SANOFI-AVENTIS (FR) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035930-A1 | UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa | TFPI, TFPI2, SERPINE1 | CPB2 61/4885CHRNB2 4855/4885CHRNB4 4861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.